Generic Endep ( Amitriptyline )

Buy Generic Endep (Amitriptyline) without prescription in Canada

In our Canadian pharmacy, you can buy Endep (Amitriptyline) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Endep (amitriptyline hydrochloride) is a tricyclic antidepressant (TCA) used primarily to treat major depressive disorder, and at lower doses, it is also widely prescribed for the management of chronic neuropathic pain, migraine prophylaxis, and tension‑type headaches. It works by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine into presynaptic nerve terminals, which increases their availability in the synaptic cleft and enhances mood‑regulating neurotransmission. This action helps relieve depression, anxiety, and certain types of persistent pain, making it a versatile option for patients whose mood disorder is accompanied by physical discomfort.

Usual adult dose: For depression, treatment is usually started at a low dose of 25 mg to 50 mg taken at bedtime, which may be gradually increased every 3 to 7 days to a total daily dose of 150 mg to 200 mg. The maximum recommended dose is 300 mg daily. For neuropathic pain, migraine prophylaxis, or insomnia, lower doses of 10 mg to 25 mg taken once daily at bedtime are often effective. Doses may be divided if daytime sedation occurs, but a single bedtime dose is preferred for most patients. The 75 mg tablet strength is typically used during dose titration in patients already established on therapy.

Dosage form: Oral tablets available in 10 mg, 25 mg, 50 mg, and 75 mg strengths. An injectable solution is also available in some clinical settings.

Onset of action: Some improvement in sleep, energy, or appetite may occur within the first 1 to 2 weeks of treatment. However, the full antidepressant effect typically requires 4 to 6 weeks of continuous therapy. Pain relief may begin within a few days to a week when used for neuropathic conditions.

Duration of action: The elimination half‑life of amitriptyline is approximately 10 to 28 hours, with its active metabolite nortriptyline having a half‑life of 18 to 44 hours. This supports once‑daily dosing at bedtime for most patients. Steady‑state plasma concentrations are achieved after approximately 3 to 7 days of regular administration.

Alcohol recommendation: Alcohol consumption should be strictly avoided during treatment with Endep. Alcohol can potentiate the central nervous system depressant effects of amitriptyline, leading to excessive sedation, impaired coordination, and an increased risk of respiratory depression. It may also worsen depression and anxiety, and the concurrent use of alcohol and amitriptyline increases the risk of suicidal thoughts or actions.

Most common side effects: Dry mouth, drowsiness, dizziness, blurred vision, constipation, difficulty urinating, and weight gain. These anticholinergic and sedative effects are often dose‑dependent and may diminish over time or with dose adjustment. Other common effects include increased appetite, fatigue, and excessive sweating.

Would you like to try Endep (Amitriptyline) without a prescription?

General Information about Endep (Amitriptyline)

• INN (International Nonproprietary Name): Amitriptyline (as amitriptyline hydrochloride).
• Brand names available in Canada: Endep® is an international brand name for amitriptyline; it is not currently marketed as a branded product in Canada. Historically, the brand names Elavil® and Levate® were marketed in Canada, but both are now cancelled post‑market. Generic formulations are widely available and include APO‑Amitriptyline (Apotex Inc.), TEVA‑Amitriptyline (Teva Canada Limited), PMS‑Amitriptyline (Pharmascience Inc.), Sandoz Amitriptyline (Sandoz Canada Inc.), JAMP‑Amitriptyline (JAMP Pharma Corporation), AA Pharma Amitriptyline (AA Pharma Inc.), and others.
• ATC code: N06AA09.
• Dosage forms and strengths: Oral tablets: 10 mg, 25 mg, 50 mg, and 75 mg (as amitriptyline hydrochloride). An injectable solution (10 mg/mL) is also available in some settings. Packs of 100 tablets are standard in Canadian pharmacies.
• Manufacturers in Canada: Apotex Inc. (APO‑Amitriptyline), Teva Canada Limited (TEVA‑Amitriptyline), Pharmascience Inc. (PMS‑Amitriptyline), Sandoz Canada Inc., JAMP Pharma Corporation, AA Pharma Inc., Strides Pharma Canada Inc., D.C. Labs Limited, and other generic pharmaceutical companies. Historically, Merck Sharp & Dohme Canada Ltd. (Elavil) and Hoffmann‑La Roche Limited (Endep in some international markets).
• Registration status in Canada: Approved by Health Canada. Multiple generic formulations are currently marketed and available by prescription. DINs include 00371009 (PRO‑AMITRIPTYLINE), 02429101, 00377880 (AMITRIPTYLINE HCL TAB 25MG, cancelled post‑market), 02462761 (STRIDES PHARMA CANADA INC, 75MG), and numerous others.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. Amitriptyline is not available over the counter in Canada and requires a valid prescription from a licensed Canadian healthcare professional.

Mechanism of Action and Pharmacology

Amitriptyline is a tertiary amine tricyclic antidepressant with a broad pharmacological profile. Its primary mechanism of action is the inhibition of the presynaptic reuptake of the monoamine neurotransmitters serotonin (5‑hydroxytryptamine, 5‑HT) and norepinephrine (NE). It is a potent inhibitor of the serotonin transporter (SERT) and a somewhat less potent inhibitor of the norepinephrine transporter (NET). By blocking these transporters, amitriptyline increases the synaptic availability of these neurotransmitters, thereby enhancing monoaminergic neurotransmission in brain regions associated with mood regulation. This action is thought to underlie both its antidepressant and analgesic effects. In the central nervous system, amitriptyline also blocks sodium channels, which contributes to its efficacy in neuropathic pain.

In addition to monoamine reuptake inhibition, amitriptyline possesses a high affinity for histamine H₁ receptors (causing significant sedation and weight gain), muscarinic cholinergic receptors (causing dry mouth, blurred vision, constipation, urinary retention, and memory difficulties), and alpha‑1 adrenergic receptors (causing orthostatic hypotension). Among the TCAs, amitriptyline is one of the most sedating and anticholinergic. Amitriptyline is metabolised in the liver primarily by cytochrome P450 isoenzymes CYP2C19 and CYP2D6 to its active metabolite, nortriptyline (a secondary amine TCA with a predominantly noradrenergic profile). The metabolism of amitriptyline is dominated by CYP2C19, while nortriptyline is further metabolised primarily by CYP2D6, making the pharmacokinetics of both drugs highly susceptible to drug‑gene interactions and drug‑drug interactions. The elimination half‑life of amitriptyline is approximately 10 to 28 hours, and that of nortriptyline is 18 to 44 hours, allowing once‑daily dosing. Therapeutic drug monitoring is recommended, with a combined target range of 100 to 250 ng/mL for amitriptyline and nortriptyline together. Amitriptyline is highly protein‑bound (approximately 95%) and is excreted primarily in the urine as metabolites.

Indications

• Major Depressive Disorder (MDD): For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. Amitriptyline may be used in hospitalised or outpatient settings.
• Neuropathic Pain (Off‑label): Amitriptyline is widely used as a first‑line agent for the management of chronic neuropathic pain, including painful diabetic neuropathy, postherpetic neuralgia, central post‑stroke pain, and phantom limb pain. Canadian clinical guidelines recommend tricyclic antidepressants, particularly amitriptyline, as first‑line pharmacotherapy for neuropathic pain.
• Migraine Prophylaxis (Off‑label): It is a first‑line prophylactic agent for the prevention of migraine headaches and tension‑type headaches. Amitriptyline is recommended alongside propranolol and nadolol as a first‑line agent for migraine prophylaxis in Canadian practice.
• Other Off‑label Uses: Insomnia (especially when associated with pain or depression), generalised anxiety disorder, panic disorder, post‑traumatic stress disorder (PTSD), irritable bowel syndrome (IBS), interstitial cystitis, fibromyalgia, and chronic low back pain. It may also be used for the management of nocturnal enuresis in children, although this indication is off‑label in Canada and requires specialist supervision.
• Amitriptyline is not approved for the treatment of bipolar depression due to the risk of precipitating a manic episode. Safety and efficacy in paediatric patients for depression have not been established.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: There are no adequate and well‑controlled studies of amitriptyline in pregnant women. Amitriptyline should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Neonates exposed to tricyclic antidepressants late in the third trimester may experience withdrawal symptoms including respiratory distress, feeding difficulties, and seizures. Women of childbearing potential should use effective contraception during treatment.
• Breastfeeding: Amitriptyline and its active metabolite nortriptyline are excreted in human breast milk in small amounts. Sedation has been reported in some nursing infants. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother. If breastfeeding is continued, the infant should be monitored for sedation, irritability, and feeding difficulties.
• Paediatrics (< 12 years): Safety and efficacy for depression have not been established in children. Use in children is reserved for specific off‑label indications such as neuropathic pain or nocturnal enuresis under specialist guidance. Antidepressants increase the risk of suicidal thinking and behaviour in children, adolescents, and young adults in short‑term studies.
• Elderly: Elderly patients are particularly sensitive to the anticholinergic, sedative, and hypotensive effects of amitriptyline. They are at increased risk for orthostatic hypotension, confusion, falls, delirium, and cardiac arrhythmias. Amitriptyline is included in the Beers Criteria as a potentially inappropriate medication for older adults due to its strong anticholinergic and sedative properties. If use is necessary, the lowest effective dose should be employed (e.g., 10 mg at bedtime), with careful monitoring. A baseline electrocardiogram (ECG) and periodic cardiac monitoring are recommended.
• Hepatic impairment: Amitriptyline is extensively metabolised by the liver. Use with caution and start with lower doses in patients with hepatic impairment, as clearance may be reduced. Liver function tests should be monitored periodically.
• Renal impairment: No dose adjustment is usually required in mild to moderate renal impairment, but caution is advised due to potential increased sensitivity to side effects. Amitriptyline has not been systematically studied in severe renal impairment.
• Cardiovascular disease: Amitriptyline should be used with extreme caution in patients with pre‑existing cardiovascular conditions, including conduction disorders, arrhythmias, recent myocardial infarction, and heart failure. TCAs can cause QT interval prolongation, tachycardia, and orthostatic hypotension. A baseline ECG should be considered before initiating therapy, and periodic monitoring is recommended, particularly at doses above 100 mg daily. Amitriptyline is contraindicated during the acute recovery phase after a myocardial infarction.
• Angle‑closure glaucoma: Amitriptyline can cause pupillary dilatation, which may trigger an acute attack of angle‑closure glaucoma in susceptible individuals. Patients at risk should have an ophthalmologic evaluation before starting therapy. It is contraindicated in patients with untreated narrow‑angle glaucoma.
• Urinary retention: Amitriptyline should be used with caution in patients with a history of urinary retention or benign prostatic hyperplasia, as its anticholinergic effects can impair bladder emptying.
• Seizure disorders: TCAs can lower the seizure threshold. Amitriptyline should be used with caution in patients with epilepsy or a history of seizures. Electroencephalogram (EEG) monitoring may be considered in high‑risk patients.
• Bipolar disorder: Screen for bipolar disorder before initiating treatment. Amitriptyline may precipitate a manic or hypomanic episode in patients with undiagnosed bipolar disorder, and TCAs are associated with a greater risk of mood switching than other classes of antidepressants. Discontinue use in any patient entering a manic phase.
• Suicidality: Antidepressants, including amitriptyline, carry a boxed warning for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults aged 24 years and under during the first few months of treatment. All patients should be closely monitored for clinical worsening, suicidality, or unusual changes in behaviour, particularly when starting therapy or after dosage changes. Families and caregivers should be advised of the need for close observation and to report concerns promptly.
• Serotonin syndrome: A potentially life‑threatening serotonin syndrome may occur with amitriptyline, particularly when combined with other serotonergic drugs. Symptoms include mental status changes (agitation, confusion, coma), autonomic instability (hyperthermia, tachycardia, labile blood pressure, diaphoresis), neuromuscular abnormalities (hyperreflexia, myoclonus, rigidity, tremor), and gastrointestinal symptoms (nausea, vomiting, diarrhoea). Immediate discontinuation of the offending agents and emergency medical care are required.
• Photosensitivity: Amitriptyline may increase the skin's sensitivity to sunlight. Patients should avoid prolonged sun exposure and use sunscreen.
• Allergy: Do not take Endep if you have a known hypersensitivity to amitriptyline hydrochloride, other dibenzazepine compounds, or any excipient in the formulation.

Driving and alcohol

Endep causes significant drowsiness, dizziness, and blurred vision, and can severely impair the mental alertness and physical coordination required for driving or operating machinery. These effects are most pronounced during the first few weeks of therapy and after dose increases. Patients should not drive, operate heavy machinery, or engage in potentially hazardous activities until they have determined how the medication affects them. Alcohol must be strictly avoided during treatment with Endep. Alcohol potentiates the central nervous system depressant effects of amitriptyline, increases the risk of profound sedation and respiratory depression, and may worsen the underlying depression or anxiety disorder. The concurrent use of amitriptyline and alcohol may also increase the risk of suicidal thoughts or actions.

Dosage Instructions

• Major Depressive Disorder (Adults): The recommended initial dose is 25 mg three times daily, or 50 mg to 75 mg as a single dose at bedtime. The dose may be increased by 25 mg to 50 mg every 3 to 7 days as tolerated, to a target range of 150 mg to 200 mg daily. The maximum recommended dose is 300 mg per day for hospitalised patients. Doses above 100 mg should be given in divided doses or as a single dose at bedtime if tolerated. After symptoms improve, the maintenance dose is typically 50 mg to 100 mg daily.
• Neuropathic Pain or Migraine Prophylaxis (Adults): Initiate at a low dose of 10 mg to 25 mg at bedtime. The dose may be titrated up by 10 mg to 25 mg weekly to a typical effective range of 25 mg to 100 mg at bedtime. Most patients with neuropathic pain achieve satisfactory relief at doses of 25 mg to 75 mg daily.
• Elderly or Debilitated Patients: Start with 10 mg at bedtime. Titrate slowly, often not exceeding 50 mg to 100 mg daily. Lower doses may be effective for both depression and pain indications in this population.
• Adolescents and Young Adults (Off‑label): The initial dose is 10 mg to 25 mg at bedtime, titrated cautiously under specialist supervision. Doses above 100 mg daily are generally not required.
• Administration: Amitriptyline tablets should be taken with a full glass of water. They may be taken with or without food, although taking with food may reduce gastrointestinal upset. If a single daily dose is prescribed, it is best taken at bedtime to minimise daytime drowsiness and to help with sleep. Swallow tablets whole; do not crush or chew. The 10 mg and 25 mg tablets are typically used for low‑dose initiation and maintenance, while the 50 mg and 75 mg tablets are used for dose escalation and higher‑dose maintenance therapy.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose.
• Discontinuation: Abrupt discontinuation should be avoided. The dose should be gradually tapered under medical supervision over several weeks to minimise the risk of withdrawal symptoms, which may include nausea, headache, malaise, irritability, and sleep disturbance.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Dry mouth, drowsiness, dizziness, weight gain, constipation, and blurred vision. These anticholinergic and sedative effects are dose‑dependent and may diminish over time, although dry mouth and constipation often persist.
• Common side effects (1‑10%): Nausea, vomiting, increased appetite, fatigue, weakness, headache, tremor, nervousness, insomnia, confusion (especially in the elderly), difficulty urinating (urinary retention), sexual dysfunction (decreased libido, erectile dysfunction, delayed ejaculation), and excessive sweating. Orthostatic hypotension is common, particularly during the first few weeks of therapy and in the elderly.
• Less common but serious side effects: Cardiac conduction disturbances (QT interval prolongation, bundle‑branch block, arrhythmias, tachycardia), syncope (fainting), orthostatic hypotension, myocardial infarction, stroke, seizures, neuroleptic malignant syndrome (NMS), agranulocytosis, leukopenia, thrombocytopenia, jaundice, hepatitis, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and photosensitivity. Activation of mania or hypomania may occur, particularly in patients with bipolar disorder.
• Overdose: An overdose of amitriptyline is a medical emergency that can be fatal. Symptoms of acute overdose include severe drowsiness, stupor, coma, respiratory depression, cardiac arrhythmias (including torsades de pointes), severe hypotension, convulsions, and cardiac arrest. Children are particularly susceptible to tricyclic antidepressant overdose, which may be fatal even at relatively low doses. Immediate hospitalisation is required, with continuous cardiac monitoring and supportive care. There is no specific antidote; treatment is symptomatic and supportive, with activated charcoal if the patient presents within 1 hour of ingestion and has a protected airway.
• Contraindications: Hypersensitivity to amitriptyline hydrochloride, other dibenzazepine compounds, or any excipient in the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue, or within 14 days of discontinuing MAOI therapy. Untreated narrow‑angle glaucoma. Acute recovery phase of a myocardial infarction. Severe urinary retention. Co‑administration with cisapride is contraindicated due to the risk of serious cardiac arrhythmias. Use of amitriptyline in patients with known cardiac conduction abnormalities should be undertaken only with extreme caution and under specialist supervision.

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs) — contraindicated: Concomitant use of amitriptyline with MAOIs (e.g., phenelzine, tranylcypromine, isocarboxazid, linezolid, intravenous methylene blue) is strictly contraindicated. This combination can cause serotonin syndrome, hypertensive crisis, and fatal reactions. A minimum 14‑day washout period must be observed between discontinuing an MAOI and starting amitriptyline, and vice versa.
• Serotonergic drugs — monitor closely: Co‑administration of amitriptyline with other serotonergic agents increases the risk of serotonin syndrome. These include selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), triptans, fentanyl, lithium, tramadol, buspirone, St. John's wort, tryptophan, and other drugs that affect serotonin. If concomitant use is clinically necessary, patients should be monitored for signs and symptoms of serotonin syndrome, especially during treatment initiation and dose increases.
• Strong CYP2D6 inhibitors — monitor and adjust: Drugs that strongly inhibit CYP2D6 (e.g., fluoxetine, paroxetine, bupropion, quinidine, terbinafine) can significantly increase amitriptyline plasma concentrations, increasing the risk of adverse effects, including cardiotoxicity. A reduction in the amitriptyline dose may be required. Therapeutic drug monitoring is recommended.
• Strong CYP2C19 inhibitors and inducers: CYP2C19 is the primary enzyme responsible for the demethylation of amitriptyline to nortriptyline. Strong CYP2C19 inhibitors can increase amitriptyline exposure, while CYP2C19 inducers (e.g., rifampin) can decrease it. Dose adjustments based on clinical response and therapeutic drug monitoring are recommended. In CYP2C19 poor metabolisers, a significant dose reduction is advised.
• CYP3A4 inducers — potential loss of efficacy: Carbamazepine, phenytoin, rifampin, and other strong CYP3A4 inducers can decrease amitriptyline plasma levels, reducing its therapeutic efficacy. An increase in the amitriptyline dose may be necessary.
• CNS depressants — additive sedation: Alcohol, benzodiazepines, opioids, sedating antihistamines, barbiturates, and other central nervous system depressants may potentiate the sedative and psychomotor‑impairing effects of amitriptyline. Patients should be advised against driving or operating machinery when such combinations are used.
• Anticholinergic agents — additive anticholinergic effects: Concomitant use of amitriptyline with other drugs possessing anticholinergic properties (e.g., antihistamines, antipsychotics, antispasmodics, oxybutynin) may increase the risk of dry mouth, constipation, blurred vision, urinary retention, and confusion, particularly in the elderly.
• Antihypertensive agents — possible antagonism: Amitriptyline may antagonise the antihypertensive effects of guanethidine, clonidine, and related compounds. Blood pressure should be monitored closely.
• Sympathomimetic agents — potentiation: Amitriptyline may potentiate the cardiovascular effects of sympathomimetic amines such as epinephrine, norepinephrine, and phenylephrine, increasing the risk of hypertension and cardiac arrhythmias. Caution is advised when co‑administering these agents, including local anaesthetics containing epinephrine.
• QT‑prolonging drugs — increased cardiac risk: Co‑administration of amitriptyline with other drugs known to prolong the QT interval (e.g., certain antiarrhythmics such as disopyramide, ibutilide, sotalol, and amiodarone; fluoroquinolone antibiotics; some antipsychotics) may increase the risk of cardiac arrhythmias, including torsades de pointes. These combinations should be avoided when possible, or used with ECG monitoring.
• Drugs that affect electrolytes: Medications that can lower potassium or magnesium levels (e.g., certain diuretics such as hydrochlorothiazide and indapamide) will increase the risk of QT prolongation and ventricular arrhythmias when used with amitriptyline. Serum electrolytes should be monitored and corrected if necessary.
• Cimetidine: May increase amitriptyline plasma levels by inhibiting hepatic metabolism. Dose adjustment of amitriptyline may be required.
• Anaesthetics: Caution is advised when amitriptyline is used with general anaesthetics, as the combination may increase the risk of cardiac arrhythmias and hypotension. Inform the anaesthetist prior to any surgery.
• Thyroid hormones: Concomitant use with thyroid hormones (e.g., levothyroxine) may increase the risk of cardiac arrhythmias due to additive effects on cardiac conduction.

Practical Advice

• Administration: Take Endep exactly as prescribed by your doctor. It may be taken with or without food; taking it with food may reduce stomach upset. If you take it once daily, take it at bedtime to minimise daytime drowsiness and to help with sleep. Swallow the tablets whole with a full glass of water; do not crush or chew.
• Monitoring: Regular follow‑up with your doctor is essential. This will include monitoring of your clinical response, particularly during the first few weeks of treatment and after dose changes. A baseline electrocardiogram (ECG) is recommended in patients with cardiac risk factors, at higher doses, or when QT‑prolonging drugs are co‑prescribed. Therapeutic drug monitoring (target range 100‑250 ng/mL for amitriptyline plus nortriptyline) is recommended for suspected toxicity, non‑adherence, or poor response. Liver function tests, complete blood counts, and serum electrolytes should be monitored periodically. Weight and body mass index should be assessed regularly, as amitriptyline commonly causes weight gain. Blood pressure should be checked at each visit, particularly during the initial titration period.
• Storage: Store at room temperature (15‑30 °C) in a tightly closed container, protected from light and moisture. Keep out of the reach and sight of children. Because of the risk of fatal overdose in children, amitriptyline must be stored with extreme care, preferably in a locked cabinet.
• Lifestyle: Rise slowly from a sitting or lying position to reduce the risk of dizziness or fainting due to orthostatic hypotension. To minimise dry mouth, sip water frequently, suck on sugarless hard candy or ice chips, chew sugarless gum, or use a saliva substitute. Maintain adequate dietary fibre and fluid intake to prevent constipation. Avoid prolonged sun exposure and use sunscreen, as amitriptyline can increase sensitivity to sunlight. Maintain a regular sleep schedule and practise good sleep hygiene. Do not drink alcohol. Endep can make you very drowsy; do not drive or operate machinery until you know its full effect on you.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is close to the time of your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed one.
• Medical emergencies: Seek immediate medical attention if you experience signs of serotonin syndrome (agitation, confusion, rapid heart rate, high fever, muscle rigidity, seizures), symptoms of a serious allergic reaction (rash, hives, swelling of the face, lips, tongue, or throat, difficulty breathing), signs of a cardiac arrhythmia (palpitations, fainting, severe dizziness), or signs of neuroleptic malignant syndrome (high fever, severe muscle stiffness, confusion). An overdose of amitriptyline is a life‑threatening emergency; call 911 or your local emergency number immediately if an overdose is suspected, particularly in a child.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Selective serotonin reuptake inhibitors (SSRIs): Sertraline (Zoloft), escitalopram (Cipralex), fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa) are first‑line antidepressants for major depressive disorder. They have a more favourable safety profile than TCAs, particularly in overdose, and fewer anticholinergic side effects. They are generally preferred over amitriptyline as initial therapy for depression.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs): Duloxetine (Cymbalta) and venlafaxine (Effexor XR) are first‑line agents for both depression and neuropathic pain, with a better tolerability profile than amitriptyline. Duloxetine is approved by Health Canada for major depressive disorder, generalised anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Milnacipran (Savella) is approved for fibromyalgia.
• Other tricyclic antidepressants (TCAs): Nortriptyline (Aventyl) is the active metabolite of amitriptyline and is often better tolerated by elderly patients, as it causes less sedation and fewer anticholinergic effects. Desipramine (Norpramin) has a predominantly noradrenergic profile. Clomipramine (Anafranil) has a strong serotonergic profile and is first‑line for obsessive‑compulsive disorder. Imipramine (Tofranil) is the original TCA with a balanced serotonergic‑noradrenergic profile. Doxepin (Sinequan) is highly sedating and is often used when insomnia accompanies depression.
• Other analgesics for neuropathic pain: Gabapentin (Neurontin) and pregabalin (Lyrica) are first‑line anticonvulsants for neuropathic pain and do not have the anticholinergic or cardiac toxicity of amitriptyline. Gabapentin and amitriptyline have been shown to be similarly effective for neuropathic pain.
• Other migraine prophylactics: Propranolol, nadolol, metoprolol (beta‑blockers), topiramate (Topamax), candesartan (Atacand), and flunarizine are first‑line options for migraine prevention. OnabotulinumtoxinA (Botox) and calcitonin gene‑related peptide (CGRP) monoclonal antibodies are reserved for chronic or refractory migraine.
• Mirtazapine (Remeron): An atypical antidepressant with a different mechanism of action that provides sedation and appetite stimulation, similar to amitriptyline, but with a lower risk of anticholinergic effects and cardiotoxicity in overdose. It lacks the analgesic benefits of amitriptyline for neuropathic pain.
• Non‑pharmacological approaches: Cognitive behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation are evidence‑based psychotherapies for depression. For chronic pain, physiotherapy, graded exercise, transcutaneous electrical nerve stimulation (TENS), acupuncture, and mindfulness‑based stress reduction can be helpful adjunctive measures. For migraine, identifying and avoiding triggers, maintaining regular sleep and meal schedules, and stress management are essential components of a comprehensive management plan.

Clinical Efficacy

Amitriptyline is one of the oldest and most extensively studied antidepressants. In numerous placebo‑controlled trials for major depressive disorder, it has consistently demonstrated superior efficacy to placebo, achieving response rates of approximately 60‑70%. A 2024 network meta‑analysis of over 450 randomised controlled trials found that amitriptyline was one of the few agents with a statistically significant higher response rate compared with both placebo and several other active comparators, placing it among the most effective antidepressants available.

For neuropathic pain, a Cochrane systematic review of 21 studies concluded that amitriptyline is effective at achieving a 50% or greater reduction in pain, with a number needed to treat (NNT) of approximately 4.3 to 4.6. This means that for every 4 to 5 patients treated, one will achieve clinically meaningful pain relief that would not have occurred with placebo. Amitriptyline remains a first‑line therapy in guidelines from the Canadian Pain Society, the International Association for the Study of Pain (IASP), and the European Federation of Neurological Societies. The strongest evidence of benefit among TCAs is for amitriptyline, imipramine, and nortriptyline.

For migraine prophylaxis, amitriptyline has been shown to reduce migraine frequency by 50% or more in a significant proportion of patients. A review of all medications for migraine prophylaxis places amitriptyline, along with propranolol and nadolol, as a first‑line agent. The benefit improves with continued therapy over time. In comparative studies, amitriptyline has demonstrated efficacy comparable to propranolol for migraine prevention, although the side‑effect profiles differ substantially.

The clinical utility of amitriptyline is often limited by its anticholinergic and sedative side effects and its danger in overdose. Approximately 1 in 5 patients taking amitriptyline for neuropathic pain will experience an adverse event, and about 1 in 11 will stop the medication because of side effects. Despite these limitations, amitriptyline remains a valuable second‑ or third‑line agent for depression—particularly for patients with melancholic features, significant insomnia, or comorbid pain—and a first‑line agent for many chronic pain conditions. Its low cost and once‑daily dosing also contribute to its ongoing clinical relevance.

Important:

Endep (amitriptyline) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It carries a boxed warning for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 24 years of age. All patients, regardless of age, should be closely monitored for clinical worsening, suicidality, or unusual changes in behaviour, particularly during the first few months of treatment and after dosage changes. This medication can cause significant drowsiness and dizziness; do not drive or operate machinery until you know how it affects you. Alcohol must be strictly avoided, as the combination can lead to severe respiratory depression, coma, and death. Amitriptyline is extremely dangerous in overdose, and even a small excess can be fatal, particularly in children; always store it securely out of the reach of children. Do not stop this medication abruptly; a gradual taper over several weeks is required to minimise withdrawal symptoms. Amitriptyline is contraindicated with MAOIs, and a 14‑day washout period must be observed. If you experience a severe allergic reaction (rash, swelling of the face, tongue, or throat, difficulty breathing), cardiac symptoms (such as fainting, an irregular or racing heartbeat), signs of serotonin syndrome (agitation, confusion, high fever, muscle rigidity, seizures), or signs of an acute angle‑closure glaucoma attack (sudden eye pain, decreased vision, halos around lights, headache, nausea), seek emergency medical attention immediately. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Endep - Shipping across Canada